As anti-GM-CSF therapies have been proposed or investigated in COPD and asthma19–21, these patient groups were also investigated since biomarkers may also be useful in patients at risk of developing aPAP induced by anti-GM-CSF therapy. Here, CSF2 is linked to chronic obstructive pulmonary disease.